Dhar Dipok Kumar, Hattori Shinji, Tonomoto Yasuhito, Shimoda Tadakazu, Kato Hoichi, Tachibana Mitsuo, Matsuura Kosho, Mitsumoto Yojiro, Little Alex G, Nagasue Naofumi
Naze Tokushukai Hospital, Amamioshima, Kagoshima, Japan.
Ann Thorac Surg. 2007 Apr;83(4):1265-72. doi: 10.1016/j.athoracsur.2006.12.003.
Node-positive patients with esophageal carcinoma constitute a heterogeneous population with a variable prognosis, which the current staging system insufficiently addresses. To that end, 863 patients with a curative resection for esophageal squamous cell carcinoma were analyzed to evaluate a useful and simple nodal classification system.
Along with standard conventional clinicopathologic factors, data for metastatic lymph node (MLN) number, metastatic to examined LN ratio (MLN ratio), and MLN size were evaluated. The greatest microscopic dimension of the metastatic tumor inside the largest MLN (MLN size) was measured on histopathologic slides. Patients with MLNs were classified into n1 (< 9 mm) and n2 (> or = 9 mm) groups, according to size of MLNs (n-stage).
The paratracheal LNs most frequently contained the largest MLN and among them the right recurrent laryngeal LNs were the most common site (81.8%). Patients were stratified into significant groups by all the nodal criteria. In multivariable analysis, MLN size n-stage and MLN ratio N-stage were the best independent predictors for disease-free and overall survival, respectively. In the disease-free survival, MLN ratio N-stage subcategories were divided into prognostic groups according to the n-stage. A combined nodal staging strategy combining the n-stage and N-stage had the strongest prognostic value and was used for the tumor-node-metastasis classification with distinct separation of patients into prognostic groups.
Results of this study indicate that the MLN size may serve as an accurate metric to classify node-positive patients and a combination of the MLN ratio and size may have synergism in classifying node-positive patients into prognostically homogenous groups.
食管癌淋巴结阳性患者构成了一个预后各异的异质性群体,当前的分期系统对此处理不足。为此,对863例行食管癌鳞状细胞癌根治性切除术的患者进行分析,以评估一种实用且简单的淋巴结分类系统。
除标准的传统临床病理因素外,还评估了转移淋巴结(MLN)数量、转移淋巴结与检查淋巴结的比例(MLN比例)以及MLN大小。在组织病理切片上测量最大MLN内转移瘤的最大微观尺寸(MLN大小)。根据MLN大小(n分期),将有MLN的患者分为n1(<9 mm)和n2(≥9 mm)组。
气管旁淋巴结最常包含最大的MLN,其中右侧喉返神经淋巴结是最常见的部位(81.8%)。根据所有淋巴结标准将患者分层为有显著差异的组。在多变量分析中,MLN大小n分期和MLN比例N分期分别是无病生存和总生存的最佳独立预测因素。在无病生存中,MLN比例N分期亚类根据n分期分为预后组。结合n分期和N分期的联合淋巴结分期策略具有最强的预后价值,并用于肿瘤-淋巴结-转移分类,能将患者明显分为不同的预后组。
本研究结果表明,MLN大小可作为对淋巴结阳性患者进行分类的准确指标,MLN比例和大小的组合在将淋巴结阳性患者分类为预后同质组方面可能具有协同作用。